These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 7775180)

  • 1. Toward a standard drug formulary for the treatment of headache.
    Klapper JA
    Headache; 1995 Apr; 35(4):225-7. PubMed ID: 7775180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Tricyclic antidepressant therapy in headache].
    Magyar M; Csépány É; Gyüre T; Bozsik G; Bereczki D; Ertsey C
    Neuropsychopharmacol Hung; 2015 Dec; 17(4):177-82. PubMed ID: 26727721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Personal formularies. An index of prescribing quality?
    Robertson J; Fryer JL; O'Connell DL; Smith AJ; Henry DA
    Eur J Clin Pharmacol; 2001 Jul; 57(4):333-41. PubMed ID: 11549213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription drug formularies in managed care: concerns for the elderly population.
    Gross DJ
    Clin Ther; 1998; 20(6):1277-91. PubMed ID: 9916619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic and prophylactic treatment of migraine and tension-type headache.
    Schulman EA; Silberstein SD
    Neurology; 1992 Mar; 42(3 Suppl 2):16-21. PubMed ID: 1557187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Maine's Medicaid drug formulary change on non-Medicaid markets: spillover effects of a restrictive drug formulary.
    Wang YR; Pauly MV; Lin YA
    Am J Manag Care; 2003 Oct; 9(10):686-96. PubMed ID: 14572179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive management of headache and depression.
    Silberstein SD
    Cephalalgia; 1998 Feb; 18 Suppl 21():50-5. PubMed ID: 9533672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Headache formulary for managed care organizations.
    Von Seggern R
    Headache; 1995 Jan; 35(1):52-3. PubMed ID: 7868341
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of formularies on clinical innovation.
    Goodwin FK
    J Clin Psychiatry; 2003; 64 Suppl 17():11-4. PubMed ID: 14680421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. General practitioners choose within a narrow range of drugs when initiating new treatments: a cohort study of cardiovascular drug formularies.
    Buusman A; Kragstrup J; Andersen M
    Eur J Clin Pharmacol; 2005 Oct; 61(9):651-6. PubMed ID: 16187132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Office management of benign headache. The science and the art.
    Silberstein SD
    Postgrad Med; 1993 Jan; 93(1):223-5, 228-30, 233-4 passim. PubMed ID: 8093415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Headache Treatment].
    Diener HC; Holle-Lee D; Nägel S; Gaul C
    Dtsch Med Wochenschr; 2017 Mar; 142(6):418-426. PubMed ID: 28329903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment.
    Sheehan DV; Wright-Etter PJ
    Manag Care Q; 2002; 10(3):21-31. PubMed ID: 12476662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An application of a proposed framework for formulary listing in low-income countries: the case of Côte d'Ivoire.
    Diaby V; Lachaine J
    Appl Health Econ Health Policy; 2011 Nov; 9(6):389-402. PubMed ID: 22017499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prophylactic treatments of migraine].
    Massiou H
    Rev Neurol (Paris); 2000; 156 Suppl 4():4S79-86. PubMed ID: 11139754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug formularies--good or evil? A view from a managed care provider.
    Giaquinta D
    Cardiology; 1994; 85 Suppl 1():30-5. PubMed ID: 7743532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
    Watkins JB; Minshall ME; Sullivan SD
    J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between FDA black box warnings and Medicare formulary coverage changes.
    Dhruva SS; Karaca-Mandic P; Shah ND; Shaw DL; Ross JS
    Am J Manag Care; 2017 Sep; 23(9):e310-e315. PubMed ID: 29087169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.